Drug interactions
Ublituximab + Upadacitinib
Severity: Major
Ublituximab and Upadacitinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents suppress immune function, and combined use may increase the risk of serious infections. The B-cell depleting effect of ublituximab persists for months after dosing.
What this interaction means in plain words
Ublituximab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Ublituximab belongs to Miscellaneous; Upadacitinib belongs to Musculoskeletal.
Why it happens
Additive immunosuppression from JAK inhibition and CD20-mediated B-cell depletion.
What to do
Avoid combining where possible; if used together, monitor closely for infection and screen for hepatitis B and tuberculosis before treatment. Interrupt upadacitinib if a serious infection develops.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ublituximab and Upadacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Upadacitinib
- Abrocitinib + Upadacitinib Contraindicated
- Adenovirus types 4 and 7 live + Upadacitinib Contraindicated
- Baricitinib + Upadacitinib Contraindicated
- Bcg vaccine live + Upadacitinib Contraindicated
- Cyclosporine + Upadacitinib Contraindicated
- Dengue vaccine + Upadacitinib Contraindicated
Other interactions of Ublituximab
Frequently asked questions
Can I take Ublituximab with Upadacitinib?
MediHelp rates the interaction as major. Ublituximab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents suppress immune function, and combined use may increase the risk of serious infections. The B-cell depleting effect of ublituximab persists for months after dosing.
How serious is the interaction between Ublituximab and Upadacitinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible; if used together, monitor closely for infection and screen for hepatitis B and tuberculosis before treatment. Interrupt upadacitinib if a serious infection develops.
What other medicines interact with Upadacitinib?
MediHelp also lists interactions of Upadacitinib with, for example, Abrocitinib, Adenovirus types 4 and 7 live, Baricitinib. The full list is on the Upadacitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
